Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wrong. Who do you think does the initial investigation? The SEC does the initial investigation and then notifies the DOJ if they believe there are actions that may warrant criminal charges. I didn't say the DOJ doesn't do investigations. I'm much closer to the is process than you may think.
Absolutely debunked, good grief.
No, the SEC does the "investigation" and the DOJ decides whether to pursue criminal charges based on the SEC's findings.
SEC doesn't do criminal violations.
Before or after they get approval to increase the authorized shares by 200m? Are you suggesting they won't be able to continue to sell shares? lol
End of October many are expecting announcements of financial difficulty.
Then why did the SEC inform the Company that this inquiry should "not" be construed as an indication that any violations of law have occurred?
No, this was the dead giveaway as to why they didn't say they were the subject of the investigation: "The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity."
Guess you missed this sentence in the 10K:
"The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity."
Based on what evidence that was released by the SEC/DOJ?
Obviously it will be Fife and/or management.
The question is - against who? There's NO evidence it will be anyone who works for CytoDyn, especially given the shorting and stock manipulation that happened last June, and many assume is the target of the investigation.
it's also valid to speculate the SEC and/or DOJ will take regulatory and/or civil, criminal action.
Not going to be good for the shareholders? I wasn't aware the target of their investigation had been announced. So, what is the target of their investigation? Links and no speculation please.
And then there is the SEC/DOJ investigation -- should be fun to watch, not going to be good for the shareholders though.
Does this qualify as a lawsuit?
Plaintiff asserts that in a follow-up telephone conversation, Mr. Rosenbaum affirmed his promise to repay his debt. ECF No. 10, PageID.107. Mr. Rosenbaum also allegedly told Plaintiff that “he would give her a check if she met him in person, alone, in a hotel room during her New Orleans vacation with friends or at another location of her choosing.”
https://law.justia.com/cases/federal/district-courts/michigan/miedce/2:2019cv12577/341333/16/
Odd, I don’t see any felonies or lost lawsuits in his past…
Is this what you're looking for? It's only two days away.
CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A
https://www.cytodyn.com/newsroom/press-releases/detail/566/cytodyn-to-present-at-emerging-growth-conference-on-october
No updates out of Brazil as promised
Why would there be "sand in our eyes"?
Wake up--get the sand out of the eyes--smell the coffee
Proactive Live alert CytoDyn Inc. - CytoDyn announces study to evaluate potential synergistic effects of Leronlimab with immune checkpoint blockade
I believe this gives more detail than the CytoDyn PR this morning.
https://www.proactiveinvestors.com/companies/news/962561/cytodyn-announces-study-to-evaluate-potential-synergistic-effects-of-leronlimab-with-immune-checkpoint-blockade-962561.html
FOUR MAJOR UPDATES TODAY: CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV
https://www.cytodyn.com/newsroom/press-releases/detail/564/cytodyn-names-chris-recknor-m-d-senior-executive-vp-of
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)
https://www.cytodyn.com/newsroom/press-releases/detail/565/cytodyn-announces-study-to-evaluate-potential-synergistic
CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research
https://www.cytodyn.com/newsroom/press-releases/detail/563/cytodyn-announces-legal-actions-against-its-former-cro
PRER14A: Preliminary revised proxy soliciting materials
https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001193125-21-293504/d246474dprer14a.htm
What "theory" are you referring to?? lol
I’ll buy this theory if you connect it to any of the following:
I have no idea as to what you're referring to.
Patterson and Beaty are no longer invested in IncellDX??? What about poor Phil Harrison?
The 7 of 71 who invested in CYDY and Incelldx are not part of the remaining few in the 13d.
$1.85 and climbing. That cat must have been made out of rubber.
Some technical support at $1.70, will the dead cat bounce?
Wrong. He said "Samsung" was paid. Samsung is not the CRO. lol
Also, as someone said on twitter, didn't Nader say on last weeks EG call that Amarex bill was paid?
So the former 13D gang of miscreants just filed a supplement to their proxy statement this morning that shows they are still against increasing shares while knowing we need to raise the authorized share count to raise funds that are required to continue our trials and pay the bills. And what is their plan to raise funds without having additional shares to sell? (insert crickets here)
It looks to me like they're not confident in getting their proposed directors on the BoD and are now focused on driving CytoDyn into bankruptcy so they can acquire Leronlimab without merging IncellDX with CytoDyn.
Why would anybody be so mindless to vote for these idiots?
Well, you gotta feel sorry for this Phillip guy buying into Rosenbomb's spiel. He stands to lose everything if the judge rules against the 13D gang of miscreants. All Rosenbomb had to do was parade Brucey around like the lead clown in the Barnum & Bailey circus to get some gullible ones to jump out of their closet and load up on IncellDX convertible notes. Maybe he'll be the one filing the next lawsuit after tomorrow.
Quote:
On October 6, 2020, Phillip Harrison, one of the individuals named as Gifting Persons in the Proxy Statement, purchased secured convertible notes (“Notes”) from IncellDx. The aggregate principal amount of notes purchased by Mr. Harrison was $200,000.
...and what about the IncellDX shares? Will they lose most of their value if the judge rules in favor of CYDY tomorrow?
According to CytoDyn's complaint against Amarex that was filed today, Amarex failed to properly categorize, organize, and analyze the data for the HIV and NASH trials, and information had no proper headings and other huge holes in the data. So CytoDyn wisely stopped paying Amarex due to its breach of obligations under the Master Services Agreement, which showed they had already paid them $80m.
From Amarex’s legal document demanding payment:
Here are some links that shows they've raised ~$14m in Sept:
https://d1io3yog0oux5.cloudfront.net/sec/0001193125-21-286887/0001193125-21-286887.pdf
https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001193125-21-266733/d201072d8k.htm
All I've seen and continue to see is speculation which proves my point.
Thanks
Feel free to share some "links" that substantiate this because most of what I see here is speculation and very little that's factual.
A company that just sold barely enough shares to pay for last summer expenses, is thus late on critical due payments and already blocked by its main CRO, has a CEO who was twice convicted and twice judged for "unjust enrichment", has missed ALL its 20 "sure bets" overs the last 4 years, including several that were in the "coming weeks", could get no approval in any country despite fantastic claims, in exchange of that dilutes massively its stock every week and uses a toxic lender, has financial statements showing that it's already bankrupting, is investigated by the SEC and Department Of Justice, is about to stop stealing from its shareholders.
A company that just sold $14m in shares last week, just posted several new job listings, has two highly active Covid trials in both severe and critical, is in the late stages of a very promising NASH trial, and is about to file a BTD for cancer is about to declare bankruptcy.
I guess the next thing we'll hear is how their headquarters offices are vacant. lol
The bankruptcy is happening.
PROSTAGENE DEBACLE ON CARACCIOLO’S WATCH
Is this the "bad man" Tony C. that you're referring to? Yeah, I have to agree. He was a mess! And now he's financially backing the hostile takeover bunch. I wonder why. Could it be because they fired him for incompetence???
The ProstaGene acquisition was essentially about a prostate cancer diagnostic. The concept of the acquisition was masterminded by Executive Anthony Caracciolo who at the time was CytoDyn’s Executive Chairman of the Board when the deal was initially announced in July 2018. Nader Pourhassan was the CEO, but at the time had no decision-making power with respect to the acquisition. Many investors may not realize, but the executive chairman is higher in rank than CEO and Caracciolo stepped into that role in January 2017. Many thought that his Gilead resume would be instrumental in inking a deal. On closing of the acquisition in November 2018 Dr. Pestell was not only welcomed as the newest board member, but was also the company’s Interim Chief Medical Officer. This was all Caracciolo’s doing until a more balanced board led by Dr. Scott Kelly came to fruition in January 2019. The fact is Caracciolo didn’t resign until January 10, 2019 when David Welch joined the board. So issues that predate January 10, 2019 are on Caracciolo’s watch, not Pourhassan’s. An interesting anecdote is that Caracciolo also presided over the failed receptor occupancy test done by IncellDX.
Yeah, today's not a good day for the few remaining 13Ders. We're up over 10% again today, and they're still hanging on to the remnants of their Uncle Bruce pipe dream.
It's hard for some to let go...
Oh my.... CYDY up again.
That's not what he said. He said "On the last call, Kelly himself said his wife sold stock!" We now know that's not true.
Yeah, a 90% increase in sp within a week is hardly something to dance a jig about! laughing...
A one-week increase when you’re under water is hardly something to dance a jig about.
Wrong!!! Kelly never said his wife has sold shares. He said "there are certain times we can purchase shares, and he's has made significant open market purchases in the past as has his wife".
On the last call, Kelly himself said his wife sold stock!
I'd rather take Dr. Laserai's word because he was in the meeting rather than speculate on what the FDA said amongst themselves and just assuming there was no push back. None of us were in the meetings and none of us know what was discussed other than what Dr. Laserai shared with us. NOBODY just "pushes back" on the FDA. And, yes, I can say that from experience.
No, actually he DID comment on it during the investors call on Oct 20, 2020.
"When we had submitted CD10 and CD12, we had proposed two doses for the Mild to Moderate patients, FOUR DOSES for the Severe and Critical and the FDA PUSHED BACK AND MADE US GIVE TWO DOSES for BOTH study populations. I’ve never actually been comfortable with that."
Lalezari said the same and then would not comment on how 2 doses came about…
No need to wait. Just submit a FOIA request like everyone else.
I'd be interested to see the FDA quote from the FDA's own mouth (or in writing) where they DENIED a 2 or 4 dose protocol.
Wrong, that's not what I said.
As Dr. Laserai said during the Oct 20, 2020 investor's call - "So as Nader said, there was the DSMC meeting last Thursday and during the intro to the meeting, I had asked the members of the committee to look at the clinical signals, mortality signals and specifically to address a question of whether we needed to adjust the dosing. When we had submitted CD10 and CD12, we had proposed two doses for the Mild to Moderate patients, FOUR DOSES for the Severe and Critical and the FDA PUSHED BACK AND MADE US GIVE TWO DOSES for BOTH study populations. I’ve I’ve never actually been comfortable with that."
“So you’re saying Nader initially requested two doses for the trial?”
Wrong - that didn't happen. As Dr. Laserai said during the Oct 20, 2020 investor's call - "So as Nader said, there was the DSMC meeting last Thursday and during the intro to the meeting, I had asked the members of the committee to look at the clinical signals, mortality signals and specifically to address a question of whether we needed to adjust the dosing. When we had submitted CD10 and CD12, we had proposed two doses for the Mild to Moderate patients, FOUR DOSES for the Severe and Critical and the FDA PUSHED BACK AND MADE US GIVE TWO DOSES for BOTH study populations. I’ve I’ve never actually been comfortable with that."
CYDY set it up as 2 doses and tried to get 4 doses half way through the trial
So you're denying the FDA refused the 2 dose protocol??? lol
That is a false CYDY/FDA narrative.
And CytoDyn is up ~90% in the last week thanks to Nader's leadership and the start of the Brazilian trials!!! Isn't that GREAT news???
You seemed to have omitted that it was the FDA that REFUSED to allow the 4 doses, and not Nader.
AND… NADER WAS ADVISED BY Dr. Patterson and Dr. Lalezari that 4 doses is needed, but Nader ran a full phase 3 trial (CD12) with only 2 doses, that failed.